Clinical Trial

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Study acronym: QuANTUM-WILD
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-03
notable Trial sites reduced: 288 -> 284 locations 2026-07-03
notable Trial sites reduced: 292 -> 288 locations 2026-05-01
Trial Details
NCT Number NCT06578247
Lead Sponsor Daiichi Sankyo
Conditions Leukemia
Enrollment 700 participants
Start Date 2024-11-19
Primary Completion 2030-06-26 (estimated)
Study Completion 2030-06-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-02